| Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling K Takada, D Zhu, GH Bird, K Sukhdeo, JJ Zhao, M Mani, M Lemieux, ... Science translational medicine 4 (148), 148ra117-148ra117, 2012 | 267 | 2012 |
| miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway JJ Zhao, J Lin, D Zhu, X Wang, D Brooks, M Chen, ZB Chu, K Takada, ... Cancer research 74 (6), 1801-1813, 2014 | 202 | 2014 |
| Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts S Bhattacharjee, F Hamberger, A Ravichandra, M Miller, A Nair, S Affo, ... The Journal of clinical investigation 131 (11), 2021 | 171 | 2021 |
| Single-cell transcriptome analysis reveals tumor immune microenvironment heterogenicity and granulocytes enrichment in colorectal cancer liver metastases Y Zhang, J Song, Z Zhao, M Yang, M Chen, C Liu, J Ji, D Zhu Cancer letters 470, 84-94, 2020 | 136 | 2020 |
| The Cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells DI Zhu, Z Wang, JJ Zhao, T Calimeri, J Meng, T Hideshima, M Fulciniti, ... Nature medicine 21 (6), 572-580, 2015 | 107 | 2015 |
| Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells M Feng, JQ Jin, L Xia, T Xiao, S Mei, X Wang, X Huang, J Chen, M Liu, ... Science advances 5 (5), eaau5240, 2019 | 87 | 2019 |
| IFNα potentiates anti–PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment B Hu, M Yu, X Ma, J Sun, C Liu, C Wang, S Wu, P Fu, Z Yang, Y He, Y Zhu, ... Cancer Discovery 12 (7), 1718-1741, 2022 | 86 | 2022 |
| Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19 C Liu, A von Brunn, D Zhu Medicine in drug discovery 7, 100056, 2020 | 83 | 2020 |
| Wnt signaling pathway in cancer immunotherapy Y Zhou, J Xu, H Luo, X Meng, M Chen, D Zhu Cancer letters 525, 84-96, 2022 | 75 | 2022 |
| Clinical cancer immunotherapy: Current progress and prospects C Liu, M Yang, D Zhang, M Chen, D Zhu Frontiers in immunology 13, 961805, 2022 | 72 | 2022 |
| T-cell-based immunotherapy in colorectal cancer M Feng, Z Zhao, M Yang, J Ji, D Zhu Cancer letters 498, 201-209, 2021 | 58 | 2021 |
| Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies Y Zhang, J Xu, N Zhang, M Chen, H Wang, D Zhu Cancer letters 458, 123-135, 2019 | 48 | 2019 |
| Circular RNA in cancer development and immune regulation W Li, JQ Liu, M Chen, J Xu, D Zhu Journal of cellular and molecular medicine 26 (6), 1785-1798, 2022 | 39 | 2022 |
| Tumor-infiltrated activated B cells suppress liver metastasis of colorectal cancers Y Xu, Z Wei, M Feng, D Zhu, S Mei, Z Wu, Q Feng, W Chang, M Ji, C Liu, ... Cell reports 40 (9), 2022 | 32 | 2022 |
| Targeting Wnt/β-catenin pathway for drug therapy C Liu, K Takada, D Zhu Medicine in Drug Discovery 8, 100066, 2020 | 31 | 2020 |
| BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer X Wang, M Feng, T Xiao, B Guo, D Liu, C Liu, J Pei, Q Liu, Y Xiao, ... Oncogene 40 (16), 2982-2997, 2021 | 23 | 2021 |
| Targeting Wnt signaling in the tumor immune microenvironment to enhancing EpCAM CAR T-cell therapy W Li, Y Zhou, Z Wu, Y Shi, E Tian, Y Zhu, T Wang, W Dou, X Meng, ... Frontiers in Pharmacology 12, 724306, 2021 | 21 | 2021 |
| Wnt/β-catenin signaling pathway in lung cancer W Zhu, H Wang, D Zhu Medicine in Drug Discovery 13, 100113, 2022 | 20 | 2022 |
| BCL9 regulates CD226 and CD96 checkpoints in CD8+ T cells to improve PD-1 response in cancer M Feng, Z Wu, Y Zhou, Z Wei, E Tian, S Mei, Y Zhu, C Liu, F He, H Li, ... Signal Transduction and Targeted Therapy 6 (1), 313, 2021 | 20 | 2021 |
| Wnt signaling in inflammation in tissue repair and regeneration Y Zhou, J Jin, M Feng, D Zhu Current Protein and Peptide Science 20 (8), 829-843, 2019 | 17 | 2019 |
